Skip to main content
. 2022 Apr 11;14(4):837. doi: 10.3390/pharmaceutics14040837

Figure 1.

Figure 1

The effect of zilovertamab (“zilo”) +/− Paclitaxel, Cisplatin, Olaparib at IC70 doses on high-grade serous ovarian cancer cell lines CaOV3, CaOV3CisR, PEO1 and PEO4. (A). Confluency of cell lines over 72 h of treatments analysed by IncuCyte S3. The confluency of each time point was normalised against the baseline. (B). Differences in cell confluency following each treatment compared with the control (vehicle for single treatment, single arm for combined therapies) at 72 h. Significance of the comparisons was assessed using two-way ANOVA with a Dunnett/Tukey correction for multiple comparison. * Adjusted p < 0.05 ** Adjusted p < 0.01, *** Adjusted p < 0.001. For each panel, n = 5, error bar = SEM.